Astellas invests $10M in Cytori; Geron plots $87M stock sale; StemCells gets green light for PhaseI/II

 @FierceBiotech:  Orexigen braces for advisory panel's Contrave review. Article | Follow @FierceBiotech

 @JohnCFierce: The panel vote favoring Allergan's lap band and the trouble Orexigen faces on risk factors underscores basic distrust of drugs for obesity. Follow @JohnCFierce

> Geron says it plans to raise $87 million in a stock sale. Report

> Astellas Pharma will invest $10 million in Cytori as it evaluates the biotech's stem cell technology. Shares of Cytori surged on news of the deal. Story

> Swiss officials have signed off on StemCells Phase I/II trial of purified human neural stem cells for chronic spinal damage. StemCells release

> Immunomedics, a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that epratuzumab, the company's humanized anti-CD22 antibody, conjugated with SN-38, the active component of irinotecan, produced significant anti-tumor responses in a mouse model of human lymphoma. Immunomedics release

And Finally... Researchers say that the DRD4 gene, already linked to alcohol use and gambling, could also play a role in spurring a propensity for brief sexual liaisons. Story

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.